Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.

Breast Cancer Research and Treatment
Bahar MoftakharAjay Dhakal

Abstract

Palbociclib is commonly added to an aromatase inhibitor (AI) as first-line therapy in ER + HER2- metastatic breast cancer (MBC). There are no data on the effect of the relative dose intensity (RDI) of palbociclib in first-line setting on clinical outcomes. The objective of this study is to explore the association of RDI and dose reduction of palbociclib in the first-line setting with PFS. This is a retrospective study of ER + HER2- MBC patients who received palbociclib plus AI in first-line setting. Subjects ≥ 18 years old with MBC, who were started on palbociclib 125 mg daily, had completed ≥ 1 cycle of palbociclib, and did not progress within the first 12 weeks were eligible. Analyses were performed at 12- and 36-week landmarks (LM). RDI was defined as the total amount of palbociclib taken per the total amount planned. RDI-high-12 and RDI-low-12 cohorts were defined as patients receiving palbociclib with RDI ≥ 80% and RDI < 80% during the first 12 weeks, respectively. Reduction-12 and No-reduction-12 cohorts were defined as patients who had any dose reduction and patients who had no reduction during the first 12 weeks, respectively. 56 patients were eligible. Kaplan-Meier analysis from 12-week LM showed a median PFS of 17.1 m...Continue Reading

References

Jan 26, 2007·Pharmacoepidemiology and Drug Safety·Samy Suissa
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R AndersonRichard D Gelber
May 19, 2011·Circulation. Cardiovascular Quality and Outcomes·Urania Dafni
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Aug 24, 2017·BMC Medical Research Methodology·In Sung ChoChung Mo Nam
Dec 9, 2017·Breast Cancer Research and Treatment·Jun GongJoanne Mortimer
Oct 23, 2018·The New England Journal of Medicine·Nicholas C TurnerMassimo Cristofanilli

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.